Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$1732.00
-17.00 (-0.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.5B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$200.0B
P/E
17.4x
↓EV/EBITDA
7.4x
↓ROE
13.2%
↑Gross Margin
29.8%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.8%
FCF CAGR
-68.7%
FCF margin
0.2%
FCF / Net income
0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $189.02B · net income $22.94B · FCF $337.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $189.02B | $189.02B | $176.86B | $163.70B | $193.82B |
| Net Income | $22.94B | $22.94B | $13.70B | $12.67B | $-28.27B |
| EBITDA | $36.20B | $36.20B | $36.88B | $33.93B | $-18.70B |
| EPS | 184.45 | 184.45 | 103.93 | 96.20 | — |
| Gross Margin | 29.8% | 29.8% | 30.7% | 30.7% | 34.4% |
| Operating Margin | 11.0% | 11.0% | 10.5% | 9.8% | -18.5% |
| Net Margin | 12.1% | 12.1% | 7.7% | 7.7% | -14.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.39 | 0.36 | 0.35 |
| Current Ratio | 2.48 | 2.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $337.0M | $337.0M | $-1.50B | $-14.12B | $10.97B |
| Returns | |||||
| ROE | 13.2% | 13.2% | 6.4% | 6.3% | -14.9% |
| Valuation | |||||
| P/E | 17.40 | 17.40 | 18.42 | 12.86 | — |
| EV/EBITDA | 7.40 | 7.40 | 8.37 | 5.98 | — |
| P/B | 1.24 | 1.24 | 1.19 | 0.81 | 0.97 |
| Growth & Yield | |||||
| Revenue Growth | 6.9% | 6.9% | 8.0% | -15.5% | — |
| EPS Growth | 77.5% | 77.5% | 8.0% | — | — |
| Dividend Yield | 3.2% | 3.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-5.9%
EPS terminal req.
$153.69
Spread vs growth
83.4%
5Y implied EPS CAGR
0.2%
EPS terminal req.
$185.96
Spread vs growth
77.3%
10Y implied EPS CAGR
5.0%
EPS terminal req.
$299.49
Spread vs growth
72.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.0%
Start / end P/E
16.9x → 9.4x
EPS bridge
103.93 → 184.45
Residual
-34.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.